Viatris agrees to acquire Pacira for $1.65B
Completion is expected by the end of 2026, subject to the tender condition and regulatory waiting period.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
8-K
Rhea-AI Filing Summary
Viatris Inc. (VTRS) agreed to acquire Pacira BioSciences for an aggregate equity value of $1.65 billion, with cash consideration of $36.50 per Pacira share through a tender offer followed by a merger. The offer has not yet commenced. Closing conditions include valid tenders together with shares already owned by Purchaser and its affiliates representing at least one share more than 50% of Pacira’s outstanding shares, expiration or termination of the Hart-Scott-Rodino waiting period, and other customary conditions; the offer has no financing condition.
The offer is to remain open for 10 business days, subject to extension in certain circumstances. Pacira’s board unanimously recommends tendering; remaining eligible shares would receive the same consideration in the merger, and Pacira would become a wholly owned Viatris subsidiary. Viatris expects closing by the end of 2026 and said it expects the deal to be immediately accretive to its financial guidance metrics. Pacira reported approximately $746 million in revenue and $177 million in adjusted EBITDA for the 12 months ended June 30, 2026.
Filing Explained
The agreement sets an April 2027 outside date and a contingent $62 million termination fee.
Viatris has signed the Pacira acquisition agreement, but the tender offer has not commenced; it expects to fund the cash purchase mainly from excess cash, with short-term borrowings for the balance.
Either party may terminate if the offer is not completed by
If the agreement is terminated in specified circumstances, Pacira must pay Viatris
8-K Event Classification
3 items: 1.01, 8.01, 9.01
3 items
Item 1.01
Entry into a Material Definitive Agreement
Business
The company signed a significant contract such as a merger agreement, credit facility, or major partnership.
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
Cash consideration per share: $36.50 per share
Aggregate equity value: $1.65 billion
Total revenue: Approximately $746 million
+3 more
6 metrics
Cash consideration per share
$36.50 per share
Consideration for eligible Pacira shares
Aggregate equity value
$1.65 billion
Viatris-Pacira transaction
Total revenue
Approximately $746 million
Pacira, 12 months ended June 30, 2026
Adjusted EBITDA
Approximately $177 million
Pacira, 12 months ended June 30, 2026
Tender offer period
10 business days
Subject to extension in certain circumstances
Termination fee
$62 million
Payable by Pacira under specified termination circumstances
Key Terms
tender offer, Hart-Scott-Rodino Act, Section 251(h), appraisal, +2 more
6 terms
tender offer regulatory
"commence a tender offer to acquire all of the outstanding shares"
A tender offer is a proposal made by a person or company to buy shares from existing shareholders at a set price, usually higher than the current market value, within a specific time frame. It matters to investors because it can lead to a change in ownership or control of a company, and shareholders must decide whether to sell their shares at the offered price.
Hart-Scott-Rodino Act regulatory
"applicable to the Offer under the Hart-Scott-Rodino Act"
A U.S. antitrust law that requires parties to large mergers and acquisitions to notify federal regulators and wait a set period before closing the deal, so authorities can check whether the transaction would unfairly reduce competition. For investors, the process is like notifying a referee before a major team trade: it can reveal objections, trigger investigations, delay or block a deal, and therefore affect transaction timing, value and deal risk.
Section 251(h) regulatory
"the Merger will be effected pursuant to Section 251(h)"
Section 251(h) is a provision in Delaware corporate law that lets a company complete a merger without holding a separate shareholder vote if a prior, qualifying tender offer already secured the required number of shares on the same terms. For investors, it matters because it shortens the timetable and reduces the risk that a merger will be blocked by a follow-up vote—think of it as a shortcut that finalizes a deal once enough stockholders have already agreed.
appraisal regulatory
"stockholders who are entitled to and properly demand appraisal"
An appraisal is a professional estimate of the monetary value of an asset, such as real estate, a business, equipment, or intellectual property, prepared by an independent expert. Investors use appraisals like a third‑party inspection before buying or lending: they help set fair prices, determine collateral for loans, inform accounting and tax entries, and reduce the risk of overpaying or understating an asset’s worth.
adjusted EBITDA financial
"approximately $177 million in adjusted EBITDA"
Adjusted EBITDA is a way companies measure how much money they make from their core operations, like running a business, by removing certain costs or income that aren’t part of regular business activities. It helps investors see how well a company is doing without distractions from unusual expenses or gains, making it easier to compare companies or track performance over time.
Superior Offer regulatory
"would reasonably be expected to lead to a Superior Offer"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What is VTRS paying to acquire Pacira?
Viatris agreed to pay $36.50 per Pacira share in cash, representing an aggregate equity value of $1.65 billion.
What were Pacira’s revenue and adjusted EBITDA before the VTRS deal?
Pacira reported approximately $746 million in total revenue and approximately $177 million in adjusted EBITDA for the 12 months ended June 30, 2026.
What termination fee could Pacira owe VTRS?
Pacira must pay Viatris a $62 million termination fee in specified circumstances, including if Pacira enters a definitive agreement for a Superior Offer or its board withdraws its recommendation in favor of the offer.
What is the deadline for the VTRS-Pacira deal to close?
Either party may terminate if the offer is not consummated on or before April 8, 2027. There is one automatic extension to July 8, 2027 if, on April 8, 2027, all conditions other than those related to antitrust approvals, governmental orders and other legal restraints have been satisfied or waived.
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 8, 2026
(Exact name of registrant as specified in its charter)
|
|
|
|
|
(State or Other Jurisdiction of Incorporation)
|
(Commission File Number)
|
(I.R.S. Employer Identification No.)
|
(Address of Principal Executive Offices)
(724 ) 514-1800
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
Trading
Symbol(s)
|
Name of each exchange
on which registered
|
||
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 1.01 |
Entry into a Material Definitive Agreement.
|
Agreement and Plan of Merger
On October 8, 2026, Viatris Inc., a Delaware corporation (“Viatris”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Pacira
BioSciences, Inc., a Delaware corporation (“Pacira”), and Peach Purchaser Sub Inc., a Delaware corporation and a wholly owned subsidiary of Viatris (“Purchaser”).
Pursuant to the Merger Agreement, and upon the terms and subject to the conditions therein, Purchaser will commence a tender offer (the “Offer”) to
acquire all of the outstanding shares of common stock, par value $0.001 per share, of Pacira (the “Shares”) for $36.50 per Share, in cash, net of applicable withholding taxes and without interest (such amount, or any higher amount per Share paid
pursuant to the Offer, the “Offer Price”). The Offer will remain open for 10 business days, subject to extension under certain circumstances.
As soon as practicable following the consummation of the Offer, Purchaser will be merged with and into Pacira (the “Merger”), with Pacira continuing as
the surviving corporation in the Merger and as a wholly owned subsidiary of Viatris, on the terms and subject to the conditions set forth in the Merger Agreement. The Merger Agreement contemplates that the Merger will be effected pursuant to Section
251(h) of the General Corporation Law of the State of Delaware (the “DGCL”), with no stockholder vote required to consummate the Merger. At the effective time of the Merger (the “Effective Time”), each Share issued and outstanding immediately prior
to the Effective Time (other than Shares (i) held by Pacira or any of its subsidiaries (including in Pacira’s treasury), (ii) held by Viatris, Purchaser or any other wholly owned subsidiary of Viatris or (iii) held by stockholders who are entitled to
and properly demand appraisal of such Shares in accordance with Section 262 of the DGCL) will be converted into the right to receive the Offer Price, upon the terms and conditions set forth in the Merger Agreement.
The obligation of Purchaser to accept for payment and pay for Shares validly tendered (and not withdrawn) pursuant to the Offer is subject to the
satisfaction or waiver of a number of conditions set forth in the Merger Agreement, including (i) that there have been validly tendered (and not validly withdrawn) prior to the expiration of the Offer a number of Shares that, considered together with
the number of Shares, if any, then owned by Purchaser and its affiliates, would represent at least one Share more than 50% of the total number of Shares then issued and outstanding (the “Minimum Condition”); (ii) the accuracy of the representations
and warranties of Pacira contained in the Merger Agreement, subject to customary thresholds and exceptions; (iii) Pacira’s compliance with, or performance of, in all material respects its covenants and agreements contained in the Merger Agreement;
(iv) the expiration or termination of the waiting period (or any extension thereof) applicable to the Offer under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”); (v) the absence of any legal restraint that
prohibits or makes illegal the consummation of the Offer or the Merger; and (vi) other customary conditions set forth in Annex I to the Merger Agreement. The Minimum Condition may not be waived by Viatris or Purchaser without the prior written
consent of Pacira. Consummation of the Offer is not subject to a financing condition.
Each of Viatris and Pacira has agreed to make an appropriate filing of all Notification and Report forms as required by the HSR Act with respect to the
transactions contemplated by the Merger Agreement promptly, and in any event within 15 business days, after the date of the Merger Agreement.
The Merger Agreement includes customary representations, warranties and covenants of Viatris, Pacira and Purchaser for a transaction of this nature,
including covenants regarding the operation of Pacira’s business until the time at which Purchaser accepts for payment Shares validly tendered (and not validly withdrawn) pursuant to the Offer (or the earlier termination of the Merger Agreement).
Pacira has also agreed to customary restrictions on its ability to solicit alternative acquisition proposals from third parties and engage in
discussions or negotiations with third parties regarding acquisition proposals. Notwithstanding these restrictions,
Pacira may under certain circumstances provide information to and participate in discussions or negotiations with third parties with respect to an
unsolicited bona fide written acquisition proposal that the board of directors of Pacira (the “Pacira Board”) has determined in good faith constitutes or would reasonably be expected to lead to a Superior Offer (as defined in the Merger Agreement),
if the failure to do so would reasonably be expected to be inconsistent with the fiduciary duties of the Pacira Board under applicable law.
The Merger Agreement also includes customary termination provisions for both Viatris and Pacira, including, among others, the right of Viatris or
Pacira to terminate for failure to consummate the Offer on or before April 8, 2027, subject to one automatic extension to July 8, 2027 if, on such date, all of the conditions to the Offer, other than those related to antitrust approvals and
governmental orders and other legal restraints, have been satisfied or waived. If the Merger Agreement is terminated under certain circumstances specified in the Merger Agreement, Pacira will be required to pay Viatris a termination fee of
$62,000,000 under specified circumstances (including in connection with Pacira’s entry into a definitive agreement with respect to a Superior Offer, or the Pacira Board withdrawing its recommendation in favor of the Offer). The parties to the Merger
Agreement are also entitled to specifically enforce the terms and provisions of the Merger Agreement.
The board of directors of Viatris and the board of directors of Purchaser have (i) determined that the Merger Agreement and the transactions contemplated thereby, including
the Offer and the Merger, are in the best interests of Viatris and Purchaser, respectively, and declared it advisable for Viatris and Purchaser, respectively, to enter into the Merger Agreement and consummate the transactions contemplated thereby,
and (ii) approved the execution, delivery and performance by Viatris and Purchaser, respectively, of the Merger Agreement and the consummation of the transactions contemplated thereby, including the Offer and the Merger.
The Pacira Board has unanimously (i) determined that the Merger Agreement and the transactions contemplated thereby, including the Offer and the
Merger, are fair to, and in the best interest of, Pacira and its stockholders, and declared it advisable for Pacira to enter into the Merger Agreement and consummate the transactions contemplated thereby, (ii) approved the execution, delivery and
performance by Pacira of the Merger Agreement and the consummation of the transactions contemplated thereby, including the Offer and the Merger, (iii) resolved that the Merger shall be effected under Section 251(h) of the DGCL, and (iv) resolved to
recommend that the stockholders of Pacira tender their Shares to Purchaser pursuant to the Offer.
The foregoing summary of the Merger Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the
Merger Agreement, which is filed as Exhibit 2.1 hereto and is incorporated herein by reference. The foregoing summary and the copy of the Merger Agreement are intended to provide information regarding the terms of the Merger Agreement and are not
intended to modify or supplement any factual disclosures about Viatris in its public reports filed with the U.S. Securities and Exchange Commission (the “SEC”). The assertions embodied in the representations and warranties included in the Merger
Agreement were made solely for purposes of such agreement and are subject to important qualifications and limitations agreed to by Viatris, Pacira and Purchaser in connection with the negotiated terms, including being qualified by confidential
disclosures made for the purposes of allocating contractual risk between the parties thereto. Moreover, certain representations and warranties were made as of a specified date, may be subject to a contractual standard of materiality different from
those generally applicable to Viatris’ SEC filings or may have been used for purposes of allocating risk among Viatris, Pacira and Purchaser rather than establishing matters as facts. Investors should not rely on the representations and warranties or
any description of them as characterizations of the actual state of facts of Viatris, Pacira, Purchaser or any of their respective subsidiaries or affiliates. Moreover, information concerning the subject matter of the representations and warranties
may change after the date of the Merger Agreement, and, unless required by applicable law, Viatris undertakes no obligation to update such information.
| Item 8.01 |
Other Events.
|
Press Release
On October 8, 2026, Viatris and Pacira issued a joint press release announcing the entry into the Merger Agreement. A copy of the press release is
attached as Exhibit 99.1 hereto and is incorporated herein by reference.
Investor Presentation
On October 8, 2026, Viatris made available an investor presentation announcing the Merger. A copy of the investor presentation is attached as Exhibit
99.2 hereto and is incorporated herein by reference.
Forward-Looking Statements
This Current Report on Form 8-K contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. These statements
are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements may include, without limitation, statements about the transaction, the expected timetable for completing the
proposed transaction, the anticipated benefits and synergies of the proposed transaction, the ability to complete the transaction or to satisfy the various closing conditions, future opportunities for Viatris or Pacira and either of their products and
any other statements regarding Viatris’ or Pacira’s future operations, strategic initiatives and priorities, restructuring activities, financial or operating results, capital allocation, dividend policy and payments, share repurchases, debt ratio and
covenants, anticipated business levels, future earnings, planned activities, anticipated growth, market opportunities, strategies, imperatives, competitions, commitments, confidence in future results, efforts to create, enhance or otherwise unlock
value, other expectations, plans, trends, outlooks, projections, prospects and targets for future periods, and any other statements that are not historical facts. Forward-looking statements may often be identified by the use of words such as “will”,
“may”, “can”, “could”, “should”, “would”, “project”, “believe”, “anticipate”, “expect”, “plan”, “estimate”, “forecast”, “potential”, “pipeline”, “intend”, “continue”, “target”, “seek” and variations of these words or comparable words.
Because forward-looking statements inherently involve known and unknown risks and uncertainties, actual future results, levels of activity, performance or achievements may
differ materially from those expressed or implied by such forward-looking statements, and there can be no assurance that estimates, assumptions and expectations will prove to have been correct. Factors that could cause or contribute to such differences
include, but are not limited to: the ability of Viatris and Pacira to meet expectations regarding the timing, completion and accounting and tax treatments of the proposed transaction; the ability of Viatris and Pacira to consummate the proposed
transaction; the conditions to the completion of the proposed transaction (including, but not limited to, that the stockholders of Pacira validly tender and not withdraw, in the aggregate, at least a majority of the Shares outstanding as of immediately
following the expiration of the Offer) not being satisfied or waived on the anticipated timeframe or at all; the regulatory approvals required for the proposed transaction not being obtained on the terms expected or on the anticipated schedule or at
all; the possibility that competing offers may be made; the possibility that Viatris may be unable to achieve the intended or expected benefits, synergies and operating efficiencies in connection with the proposed transaction within the expected
timeframe or at all or to successfully integrate Viatris and Pacira; Viatris’ or Pacira’s failure to achieve expected or targeted future financial and operating performance and results; the possibility that Viatris or Pacira may not realize the
intended benefits of, or achieve the intended goals or outlooks with respect to, its strategic initiatives and priorities; actions and decisions of healthcare and pharmaceutical regulators; changes in relevant laws, regulations and policies and/or the
application or implementation thereof, including but not limited to tax, healthcare and pharmaceutical laws, regulations and policies globally; the ability to attract, motivate and retain key personnel; Viatris’ or Pacira’s liquidity, capital resources
and ability to successfully complete capital projections and obtain financing; Viatris’ or Pacira’s plans with respect to the repayment of indebtedness; any regulatory, legal or other impediments to Viatris’ or Pacira’s ability to bring new products to
market; success of clinical trials and Viatris’ or Pacira’s (or, with respect to each, its partners’) ability to execute on new product opportunities and develop, manufacture and commercialize products; any changes in or difficulties with Viatris’ or
Pacira’s manufacturing facilities, including with respect to short- or long-term shutdowns, inspections, remediation and restructuring activities, product labeling or regulatory compliance, supply chain continuity, inventory management, or the ability
to meet anticipated demand; the scope, timing and outcome of any ongoing legal proceedings, including government inquiries or investigations, and the impact of any such proceedings on Viatris or Pacira; any significant breach of data security or data
privacy or disruptions to Viatris’ or Pacira’s information technology systems; risks associated with having significant operations globally; the strength and ability to protect Viatris’ or Pacira’s intellectual property and patent terms and preserve
their respective intellectual property rights; changes in third-party relationships; the effect of any changes in Viatris’ or Pacira’s (or, with respect to each, its partners’) customer and supplier relationships and customer purchasing patterns,
including customer loss and business disruption being greater than expected following the proposed transaction; the impacts of competition, including decreases in sales or revenues as a result of the loss of market exclusivity for certain products;
changes in the economic and financial conditions of Viatris or Pacira (or, with respect to each, its partners); uncertainties regarding future demand, pricing and reimbursement for Viatris’ or Pacira’s products; uncertainties and matters beyond the
control of management, including but not limited to general political and economic conditions, wars or other conflicts, potential for adverse impacts from future tariffs and trade restrictions, inflation rates, interest rates and global exchange rates;
and inherent uncertainties involved in the estimates and judgments used in the preparation of financial statements, and the providing of estimates of financial measures, in accordance with U.S. GAAP and related standards or on an adjusted basis.
For more detailed information on the risks and uncertainties associated with Viatris and Pacira, see the risks described in Part I, Item 1A of their respective Annual Reports
on Form 10-K for the year ended December 31, 2025, and their other filings with the SEC. You can access their respective filings with the SEC through the SEC website at www.sec.gov or through their respective websites, and each of Viatris and Pacira
strongly encourages you to do so. Viatris routinely posts information that may be important to investors on our website at investor.viatris.com, and we use this website address as a means of disclosing material information to the public in a broad,
non-exclusionary manner for purposes of the SEC’s Regulation Fair Disclosure (Reg FD). The contents of our website are not incorporated into this Current Report on Form 8-K or our filings with the SEC. Each of Viatris and Pacira undertakes no
obligation to update any statements herein for revisions or changes after the date of this Current Report on Form 8-K other than as required by law.
Important Information about the Transaction and Where to Find It
The tender offer for the Shares described in this Current Report on Form 8-K has not yet commenced. This Current Report on Form 8-K is for informational
purposes only and it is neither a recommendation, nor an offer to purchase nor a solicitation of an offer to sell Shares, nor is it a substitute for the tender offer materials that Viatris will file with the SEC on Schedule TO. At the time any such
tender offer is commenced, Viatris will prepare and file a Tender Offer Statement, containing an offer to purchase, a form of letter of transmittal and other related tender offer documents, with the SEC, and Pacira will file a
Solicitation/Recommendation Statement on Schedule 14D-9 relating to such tender offer with the SEC. The Offer will only be made pursuant to the offer to purchase, the letter of transmittal and other related tender offer documents filed as a part of
the Schedule TO. Pacira’s stockholders are strongly advised to read these tender offer materials carefully and in their entirety when they become available, as they may be amended or supplemented from time to time,
because they will contain important information about such tender offer that Pacira’s stockholders should consider prior to making any decisions with respect to such tender offer, including the terms and conditions of the tender offer. The
offer to purchase, letter of transmittal and other related tender offer documents, as well as the Solicitation/Recommendation Statement on Schedule 14D-9, will be sent to all stockholders of Pacira at no expense to them.
Once filed, stockholders of Pacira will be able to obtain a free copy of these documents and each of Viatris’ and Pacira’s other documents filed with the SEC at the website maintained by the SEC at www.sec.gov. In addition, a copy of the offer to
purchase, form of letter of transmittal and other related tender offer documents (once they become available) may be obtained free of charge by directing a request to Viatris at InvestorRelations@viatris.com. A copy of the Solicitation/Recommendation
Statement on Schedule 14D-9 (once it becomes available) also may be obtained free of charge by directing a request to Pacira at secretary@pacira.com.
Item 9.01 Financial Statements
and Exhibits.
|
(d)
|
Exhibits.
|
|
Exhibit No.
|
Description
|
|
2.1*
|
Agreement and Plan of Merger, dated as of October 8, 2026, by and among Pacira BioSciences, Inc., Viatris Inc. and Peach Purchaser Sub Inc.
|
|
99.1
|
Joint Press Release, dated October 8, 2026, issued by Viatris Inc. and Pacira BioSciences, Inc.
|
|
99.2
|
Investor Presentation, dated October 8, 2026, prepared by Viatris Inc.
|
|
104
|
Cover Page Interactive Data File – the cover page XBRL tags are embedded within the Inline XBRL document
|
* Schedules, exhibits and similar attachments have been omitted pursuant to Item 601(a)(5) of Regulation S-K. Viatris hereby agrees to supplementally
furnish to the SEC upon request any omitted schedule, exhibit or similar attachment to Exhibit 2.1.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
VIATRIS INC.
|
||
|
Date: October 8, 2026
|
By:
|
/s/ Matthew J. Maletta
|
|
Matthew J. Maletta
|
||
|
Chief Legal Officer
|
||
Exhibit 99.1
 |
 |
Viatris Agrees to Acquire Pacira BioSciences, Advancing Its Innovative Medicines Strategy and Becoming a Leader
in Non-Opioid Pain Therapies
| • |
Adds Two Marketed, Patent-Protected, High-Margin Medicines in the U.S., EXPAREL® and ZILRETTA®, and Expects to Expand the Products’ Reach Across Selected Markets Within Its International Infrastructure
|
| • |
Expands U.S. Innovative Medicines Commercial, Market Access, Medical Affairs and Global R&D Capabilities
|
| • |
Expected to Be Synergistic With Viatris’ Fast-Acting Meloxicam Opportunity
|
| • |
Deal Anticipated to Close By the End of 2026 and to Be Immediately Accretive to Viatris’ Financial Guidance Metrics
|
| • |
Transaction Consistent With Viatris’ Disciplined and Balanced Capital Allocation Strategy and Preserves Financial Flexibility
|
PITTSBURGH and BRISBANE, Calif. – Oct. 8, 2026 – Viatris Inc. (Nasdaq: VTRS), a global healthcare company, and Pacira BioSciences, Inc. (Nasdaq: PCRX), a leader in innovative non-opioid pain therapies, today
announced that they have entered into a definitive agreement under which Viatris has agreed to acquire all of the outstanding shares of common stock of Pacira for $36.50 per share in cash, representing an aggregate equity value of $1.65 billion.
Pacira brings two established, high-margin, patent-protected, in-market U.S. products – EXPAREL® (bupivacaine liposome injectable suspension) and
ZILRETTA® (triamcinolone acetonide extended-release injectable suspension). Pacira generated approximately $746 million in total revenue and approximately $177 million in adjusted EBITDA during the last twelve months ended June 30, 2026. Viatris
plans to leverage its intellectual property expertise and proven ability to extend product lifecycles and sustain meaningful sales after the entry of competition to maximize the long-term value of the Pacira portfolio and expects to expand the
products’ reach across select markets within its global infrastructure.
1
“The pending acquisition of Pacira BioSciences is an important step in advancing our strategy to build our innovative medicines business,” said Scott A. Smith, CEO, Viatris. “The addition of EXPAREL, for acute postsurgical pain, and ZILRETTA, for osteoarthritis knee pain, are synergistic with our fast-acting
meloxicam market opportunity and position us as a leader in non-opioid pain management therapies, an area where patients and healthcare providers continue to seek more treatment options. Pacira also brings Viatris additional U.S. innovative
commercial, market access, medical affairs and global R&D capabilities that are highly complementary to our existing infrastructure and portfolio. This transaction accelerates our path to sustained revenue and earnings growth and adds an
innovative development pipeline in certain high-value, specialty-driven therapeutic areas with a high unmet need.”
“The proposed transaction is expected to be immediately accretive to our financial guidance metrics,” said Paul
Campbell, Interim CFO, Chief Accounting Officer & Corporate Controller, Viatris. “Importantly, we expect to fund the transaction primarily from excess cash with the remainder from short-term
borrowings. As such, we expect the transaction will have minimal impact on our gross leverage ratio. We believe the transaction is consistent with our disciplined and balanced approach to capital allocation, preserves our financial flexibility and
provides opportunities to create additional value through both cost and revenue synergies.”
“Our mission from the start has been to deliver innovative, non-opioid pain therapies to transform the lives of patients. Pacira has helped reshape
pain management by advancing awareness, expanding patient access and driving the adoption of opioid-sparing therapies,” said Frank D. Lee, CEO, Pacira BioSciences. “I am immensely proud of what our team has accomplished, from building a leading
commercial portfolio that has helped nearly 20 million patients access non-opioid pain management, to advancing our 5x30 strategy and expanding our innovative pipeline. As we enter this next chapter, we are confident that Viatris’ shared vision,
substantial resources, and global scale will accelerate the impact of our mission and help bring our transformative therapies to even more patients.”
A presentation with further details about the transaction can be found at investor.viatris.com.
Terms of the Transaction
Under the terms of the transaction, Viatris will commence a tender offer to acquire all of the outstanding shares of Pacira’s common stock for $36.50
per share in cash. Following completion of the tender offer, Viatris will acquire all remaining shares of Pacira’s common stock not tendered in the tender offer through a second-step merger for the same consideration.
The transaction, which was unanimously approved by the boards of directors of both companies, is subject to customary closing conditions, including the
tender of a majority of the outstanding shares of Pacira’s common stock and expiration of the applicable regulatory waiting period. Pacira’s board of directors unanimously recommends that Pacira’s stockholders tender their shares in the tender offer.
The transaction is expected to close by the end of 2026.
Upon completion of the transaction, Pacira will become a wholly owned subsidiary of Viatris and Pacira’s common stock will no longer be listed for
trading on the Nasdaq Global Select Market.
Advisors
Morgan Stanley & Co. LLC is serving as financial advisor to Viatris, and Cravath, Swaine & Moore LLP is serving as legal advisor. Centerview
Partners LLC also provided strategic and financial advice to Viatris.
2
Goldman Sachs & Co. LLC is serving as exclusive financial advisor to Pacira, and Ashurst Perkins Coie is serving as legal advisor.
Third-Quarter Conference Call
As previously announced, Viatris will report third-quarter 2026 financial results on Thursday, Nov. 5, 2026. Company executives will host a conference
call and live webcast at 8:30 a.m. ET on the same date to discuss Viatris’ quarterly results and the Pacira transaction. Investors and the general public are invited to listen to a live webcast of the call at investor.viatris.com or by
calling 844.308.3344 or 412.317.1896 for international callers. A replay of the webcast also will be available on the website.
About Viatris
Viatris Inc. (Nasdaq: VTRS) is a global healthcare company whose mission is to empower people worldwide to live healthier at every stage of
life. We meet the needs of patients around the world by acting decisively with ingenuity and resolve. Whether we’re developing new medicines, working to maintain a resilient supply of needed therapies, or pursuing bold innovation, we strive to
deliver solutions that are effective at scale and built to endure. We’re purpose-built to make an impact with a broad portfolio that spans generics, value-added medicines, established brands and innovative medicines that address areas of significant
unmet need. We are headquartered in the U.S., with global centers in Pittsburgh, Shanghai and Hyderabad, India. Learn more at viatris.com and investor.viatris.com, and connect with us on LinkedIn, Instagram, YouTube
and X.
About Pacira BioSciences
Pacira BioSciences, Inc. (Nasdaq: PCRX) delivers innovative, non-opioid pain therapies to transform the lives of patients. Pacira has two
commercial-stage non-opioid treatments: EXPAREL® (bupivacaine liposome injectable suspension), a long-acting local analgesic for post-surgical pain management and ZILRETTA® (triamcinolone acetonide extended-release injectable suspension), an
extended-release, intra-articular injection indicated for the management of osteoarthritis knee pain. Pacira is also advancing a pipeline of clinical-stage assets for musculoskeletal pain and adjacencies. Its most advanced product candidate, PCRX-201
(enekinragene inzadenovec), a novel locally administered gene therapy, is in Phase 2 clinical development for osteoarthritis of the knee. To learn more about Pacira, visit www.pacira.com.
About EXPAREL® (bupivacaine liposome injectable suspension)
EXPAREL is indicated to produce postsurgical local analgesia via infiltration in patients aged 6 years and older, and postsurgical regional analgesia
via an interscalene brachial plexus block in adults, a sciatic nerve block in the popliteal fossa in adults, and an adductor canal block in adults. The safety and effectiveness of EXPAREL have not been established to produce postsurgical regional
analgesia via other nerve blocks besides an interscalene brachial plexus nerve block, a sciatic nerve block in the popliteal fossa, or an adductor canal block. The product combines bupivacaine with multivesicular liposomes, a proven product delivery
technology that delivers medication over a desired time period. EXPAREL represents the first and only multivesicular liposome local anesthetic that can be utilized in the peri- or postsurgical setting. By utilizing the multivesicular liposome
platform, a single dose of EXPAREL delivers bupivacaine over time, providing significant reductions in cumulative pain scores with up to a 78 percent decrease in opioid consumption; the clinical benefit of the opioid reduction was not demonstrated.
Additional information is available at www.EXPAREL.com.
3
Important Safety Information about EXPAREL for Patients
EXPAREL should not be used in obstetrical paracervical block anesthesia. In studies in adults where EXPAREL was injected into a wound, the most common
side effects were nausea, constipation, and vomiting. In studies in adults where EXPAREL was injected near a nerve, the most common side effects were nausea, fever, and constipation. In the study where EXPAREL was given to children, the most common
side effects were nausea, vomiting, constipation, low blood pressure, low number of red blood cells, muscle twitching, blurred vision, itching, and rapid heartbeat. EXPAREL can cause a temporary loss of feeling and/or loss of muscle movement. How
much and how long the loss of feeling and/or muscle movement depends on where and how much of EXPAREL was injected and may last for up to 5 days. EXPAREL is not recommended to be used in patients younger than 6 years old for injection into the wound,
for patients younger than 18 years old, for injection near a nerve, and/or in pregnant women. Tell your health care provider if you or your child has liver disease, since this may affect how the active ingredient (bupivacaine) in EXPAREL is
eliminated from the body. EXPAREL should not be injected into the spine, joints, or veins. The active ingredient in EXPAREL can affect the nervous system and the cardiovascular system; may cause an allergic reaction; may cause damage if injected into
the joints; and can cause a rare blood disorder.
About ZILRETTA® (triamcinolone acetonide extended-release injectable suspension)
On October 6, 2017, ZILRETTA was approved by the U.S. Food and Drug Administration as the first and only extended-release intra-articular therapy for
patients confronting osteoarthritis (OA)-related knee pain. ZILRETTA employs proprietary microsphere technology combining triamcinolone acetonide—a commonly administered, short-acting corticosteroid—with a poly lactic-co-glycolic acid (PLGA) matrix
to provide extended pain relief. The pivotal Phase 3 trial on which the approval of ZILRETTA was based showed that ZILRETTA significantly reduced OA knee pain for 12 weeks, with some people experiencing pain relief through Week 16. Learn more at www.zilretta.com.
Indication and Select Important Safety Information for ZILRETTA
Indication: ZILRETTA is indicated as an intra-articular injection for the management of OA pain of the knee. Limitation of Use: The efficacy and safety of repeat administration of ZILRETTA have not been demonstrated.
Contraindication: ZILRETTA is contraindicated in patients who are hypersensitive to triamcinolone acetonide, corticosteroids or any components of the product.
Warnings and Precautions:
| • |
Intra-articular Use Only: ZILRETTA has not been evaluated and should not be administered by epidural, intrathecal, intravenous, intraocular, intramuscular, intradermal, or subcutaneous routes. ZILRETTA should not be
considered safe for epidural or intrathecal administration.
|
4
| • |
Serious Neurologic Adverse Reactions with Epidural and Intrathecal
Administration: Serious neurologic events have been reported following epidural or intrathecal corticosteroid administration. Corticosteroids are
not approved for this use.
|
| • |
Hypersensitivity reactions: Serious reactions have been reported with triamcinolone acetonide injection. Institute appropriate care if an anaphylactic reaction occurs.
|
| • |
Joint infection and damage: A marked increase in joint pain, joint swelling, restricted motion, fever and malaise may suggest septic arthritis. If this occurs, conduct appropriate evaluation and if confirmed, institute
appropriate antimicrobial treatment.
|
Adverse Reactions: The most commonly reported adverse reactions (incidence ≥1%) in clinical studies included sinusitis, cough, and contusions.
Please see ZILRETTALabel.com for full Prescribing Information.
Forward-Looking Statements
This communication contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. These
statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements may include, without limitation, statements about the transaction (in which, among other things,
Viatris, through its wholly-owned subsidiary, will commence a tender offer to acquire all of the outstanding shares of common stock, $0.001 par value per share, of Pacira and, following the consummation of such tender offer, for such wholly-owned
subsidiary of Viatris to be merged with and into Pacira), the expected timetable for completing the proposed transaction, the anticipated benefits and synergies of the proposed transaction, the ability to complete the transaction or to satisfy the
various closing conditions, future opportunities for Viatris or Pacira and either of their products and any other statements regarding Viatris’ or Pacira’s future operations, strategic initiatives and priorities, restructuring activities, financial
or operating results, capital allocation, dividend policy and payments, share repurchases, debt ratio and covenants, anticipated business levels, future earnings, planned activities, anticipated growth, market opportunities, strategies, imperatives,
competitions, commitments, confidence in future results, efforts to create, enhance or otherwise unlock value, other expectations, plans, trends, outlooks, projections, prospects and targets for future periods, and any other statements that are not
historical facts. Forward-looking statements may often be identified by the use of words such as “will”, “may”, “can”, “could”, “should”, “would”, “project”, “believe”, “anticipate”, “expect”, “plan”, “estimate”, “forecast”, “potential”, “pipeline”,
“intend”, “continue”, “target”, “seek” and variations of these words or comparable words.
5
Because forward-looking statements inherently involve known and unknown risks and uncertainties, actual future results, levels of activity, performance
or achievements may differ materially from those expressed or implied by such forward-looking statements, and there can be no assurance that estimates, assumptions and expectations will prove to have been correct. Factors that could cause or
contribute to such differences include, but are not limited to: the ability of Viatris and Pacira to meet expectations regarding the timing, completion and accounting and tax treatments of the proposed transaction; the ability of Viatris and Pacira
to consummate the proposed transaction; the conditions to the completion of the proposed transaction (including, but not limited to, that the stockholders of Pacira validly tender and not withdraw, in the aggregate, at least a majority of the shares
of Pacira’s common stock outstanding as of immediately following the expiration of the tender offer) not being satisfied or waived on the anticipated timeframe or at all; the regulatory approvals required for the proposed transaction not being
obtained on the terms expected or on the anticipated schedule or at all; the possibility that competing offers may be made; the possibility that Viatris may be unable to achieve the intended or expected benefits, synergies and operating efficiencies
in connection with the proposed transaction within the expected timeframe or at all or to successfully integrate Viatris and Pacira; Viatris’ or Pacira’s failure to achieve expected or targeted future financial and operating performance and results;
the possibility that Viatris or Pacira may not realize the intended benefits of, or achieve the intended goals or outlooks with respect to, its strategic initiatives and priorities; actions and decisions of healthcare and pharmaceutical regulators;
changes in relevant laws, regulations and policies and/or the application or implementation thereof, including but not limited to tax, healthcare and pharmaceutical laws, regulations and policies globally; the ability to attract, motivate and retain
key personnel; Viatris’ or Pacira’s liquidity, capital resources and ability to successfully complete capital projections and obtain financing; Viatris’ or Pacira’s plans with respect to the repayment of indebtedness; any regulatory, legal or other
impediments to Viatris’ or Pacira’s ability to bring new products to market; success of clinical trials and Viatris’ or Pacira’s (or, with respect to each, its partners’) ability to execute on new product opportunities and develop, manufacture and
commercialize products; any changes in or difficulties with Viatris’ or Pacira’s manufacturing facilities, including with respect to short- or long-term shutdowns, inspections, remediation and restructuring activities, product labeling or regulatory
compliance, supply chain continuity, inventory management, or the ability to meet anticipated demand; the scope, timing and outcome of any ongoing legal proceedings, including government inquiries or investigations, and the impact of any such
proceedings on Viatris or Pacira; any significant breach of data security or data privacy or disruptions to Viatris’ or Pacira’s information technology systems; risks associated with having significant operations globally; the strength and ability to
protect Viatris’ or Pacira’s intellectual property and patent terms and preserve their respective intellectual property rights; changes in third-party relationships; the effect of any changes in Viatris’ or Pacira’s (or, with respect to each, its
partners’) customer and supplier relationships and customer purchasing patterns, including customer loss and business disruption being greater than expected following the proposed transaction; the impacts of competition, including decreases in sales
or revenues as a result of the loss of market exclusivity for certain products; changes in the economic and financial conditions of Viatris or Pacira (or, with respect to each, its partners); uncertainties regarding future demand, pricing and
reimbursement for Viatris’ or Pacira’s products; uncertainties and matters beyond the control of management, including but not limited to general political and economic conditions, wars or other conflicts, potential for adverse impacts from future
tariffs and trade restrictions, inflation rates, interest rates and global exchange rates; and inherent uncertainties involved in the estimates and judgments used in the preparation of financial statements, and the providing of estimates of financial
measures, in accordance with U.S. GAAP and related standards or on an adjusted basis.
6
For more detailed information on the risks and uncertainties associated with Viatris and Pacira, see the risks described in Part I, Item 1A of their
respective Annual Reports on Form 10-K for the year ended December 31, 2025, and their other filings with the U.S. Securities and Exchange Commission (the “SEC”). You can access their respective filings with the SEC through the SEC website at
www.sec.gov or through their respective websites, and each of Viatris and Pacira strongly encourages you to do so. Viatris routinely posts information that may be important to investors on our website at investor.viatris.com, and we use this
website address as a means of disclosing material information to the public in a broad, non-exclusionary manner for purposes of the SEC’s Regulation Fair Disclosure (Reg FD). The contents of our website are not incorporated into this communication or
our filings with the SEC. Each of Viatris and Pacira undertakes no obligation to update any statements herein for revisions or changes after the date of this communication other than as required by law.
Non-GAAP Financial Measures
This communication includes the presentation and discussion of certain financial information that differs from what is reported under accounting
principles generally accepted in the United States (“U.S. GAAP”). These non-GAAP financial measures, including, but not limited to, adjusted EBITDA, adjusted earnings per share (“EPS”), free cash flow excluding transaction-related and
restructuring-related costs, and gross leverage ratio, are presented in order to supplement investors’ and other readers’ understanding and assessment of the financial performance of Viatris and Pacira, as applicable.
Viatris
Free cash flow refers to U.S. GAAP net cash provided by operating activities less capital expenditures. Free cash flow excluding transaction-related
costs or restructuring-related costs refers to free cash flow further adjusted to exclude transaction-related costs and restructuring-related costs, as applicable. Adjusted EBITDA refers to U.S. GAAP net earnings (loss) adjusted for income tax
provision (benefit), interest expense and depreciation and amortization (to calculate EBITDA), and further adjusted for share-based compensation expense, litigation settlements and other contingencies, net, loss on divestitures of businesses,
impairment of goodwill and restructuring, acquisition and divestiture-related and other special items. Adjusted EPS refers to adjusted net earnings (loss) divided by the weighted average number of diluted shares of common stock outstanding. Adjusted
net earnings (loss) refers to U.S. GAAP net (loss) earnings adjusted for purchase accounting amortization; impairment of goodwill; litigation settlements and other contingencies, net; interest expense; loss on divestitures of businesses; acquisition
and divestiture-related costs; restructuring costs; share-based compensation expense; other special items included in cost of sales, research and development expense, selling, general and administrative expense, other (income) expense, net; and tax
effect of the above items and other income tax related items. Gross leverage ratio refers to the ratio of notional gross debt to adjusted EBITDA. Notional gross debt is the sum of Viatris’ long-term debt, including current portion, and short-term
borrowings and other current obligations, adjusted for net premiums on various debt issuances and deferred financing fees.
7
Viatris is not providing forward-looking financial guidance metrics for U.S. GAAP net earnings (loss), U.S. GAAP diluted EPS or U.S. GAAP net cash
provided by operating activities because it is unable to predict with reasonable certainty the ultimate outcome of certain significant items, including integration, acquisition and divestiture-related expenses, restructuring expenses, asset
impairments, litigation settlements, future share repurchases, and other contingencies, such as changes to contingent consideration, acquired in-process research and development (“IPR&D”) and certain other gains or losses as well as related
income tax accounting, because certain of these items have not occurred, are out of Viatris’ control and/or cannot be reasonably predicted without unreasonable effort. These items are uncertain, depend on various factors, and could have a material
impact on U.S. GAAP reported results for a guidance period. Investors and other readers should consider non-GAAP measures only as supplements to, not as substitutes for or as superior measures to, the measures of financial performance prepared in
accordance with U.S. GAAP.
Pacira BioSciences
This press release contains a Pacira financial measure that does not comply with U.S. GAAP, adjusted EBITDA (earnings before interest, taxes,
depreciation and amortization), because this non-GAAP financial measure excludes the impact of items that Pacira’s management believes affect comparability or underlying business trends.
This measure supplements Pacira’s financial results prepared in accordance with U.S. GAAP. Pacira management uses this measure to better analyze its
financial results and to help make managerial decisions. In Pacira’s management’s opinion, this non-GAAP measure is useful to investors and other users of Pacira’s financial statements by providing greater transparency into the ongoing operating
performance of Pacira and its future outlook. Such a measure should not be deemed to be an alternative to U.S. GAAP requirements or a measure of liquidity for Pacira. The non-GAAP measure presented here is also unlikely to be comparable with non-GAAP
disclosures released by other companies.
The Pacira financial measures included herein are consistent with such measures as reported in Pacira’s earnings releases as furnished to the SEC. A
reconciliation of Pacira’s adjusted EBITDA, a non-GAAP financial measure, to the most directly comparable U.S. GAAP financial measure, U.S. GAAP net income (loss), is set forth below.
PACIRA BIOSCIENCES, INC.
RECONCILIATION OF U.S. GAAP NET INCOME TO ADJUSTED EBITDA
|
Three Months Ended
|
Twelve
Months
Ended
|
|||||||||||||||||||
|
(in Millions)
(Unaudited)
|
September 30, 2025
|
December 31, 2025
|
March 31, 2026
|
June 30, 2026
|
June 30, 2026
|
|||||||||||||||
|
GAAP Net Income
|
$
|
5.4
|
$
|
1.6
|
$
|
2.9
|
$
|
4.7
|
$
|
14.6
|
||||||||||
|
Interest Income
|
(8.5
|
)
|
(2.3
|
)
|
(1.9
|
)
|
(1.9
|
)
|
(14.7
|
)
|
||||||||||
|
Interest Expense
|
4.3
|
3.9
|
3.7
|
3.6
|
15.5
|
|||||||||||||||
|
Income Tax Expense
|
4.1
|
(1.1
|
)
|
2.1
|
(2.1
|
)
|
3.0
|
|||||||||||||
|
Depreciation Expense
|
6.9
|
7.0
|
7.0
|
7.0
|
27.9
|
|||||||||||||||
|
Amortization of Acquired Intangible Assets
|
14.3
|
14.3
|
14.3
|
14.3
|
57.3
|
|||||||||||||||
|
EBITDA
|
26.5
|
23.5
|
28.1
|
25.5
|
103.6
|
|||||||||||||||
|
Other Adjustments:
|
||||||||||||||||||||
|
Divestiture and Acquisition-Related Expenses, and Other
|
7.3
|
1.4
|
0.9
|
6.5
|
16.1
|
|||||||||||||||
|
Changes in the Fair Value of Contingent Consideration
|
0.6
|
0.2
|
(2.3
|
)
|
1.7
|
0.2
|
||||||||||||||
|
Stock-Based Compensation
|
14.0
|
13.5
|
13.5
|
15.0
|
56.0
|
|||||||||||||||
|
Loss on Early Extinguishment of Debt
|
1.0
|
-
|
-
|
-
|
1.0
|
|||||||||||||||
|
Adjusted EBITDA
|
$
|
49.4
|
$
|
38.7
|
$
|
40.2
|
$
|
48.7
|
$
|
177.0
|
||||||||||
8
Certain Key Terms and Presentation Matters
Financial guidance metrics: Refers to Viatris total revenues, adjusted EBITDA, free cash flow excluding transaction-related and restructuring-related
costs and adjusted EPS. Financial guidance metrics exclude any acquired IPR&D for unsigned deals to be incurred in any future period as it cannot be reasonably forecasted.
Transaction-related costs: Refers to the impact of any acquisition- and divestiture-related transaction costs, including taxes.
Restructuring-related costs: Refers to the impact of any cash costs associated with the restructuring activities of the enterprise-wide strategic
review, which are expected to be primarily related to severance and employee benefits expense, as well as other costs, including those related to contract terminations, vendor consolidations, product transfer costs and network-related simplification
and modernization costs.
Important Information about the Transaction and Where to Find It
The tender offer for the outstanding shares of Pacira’s common stock described in this communication has not yet commenced. This document is for
informational purposes only and it is neither a recommendation, nor an offer to purchase nor a solicitation of an offer to sell shares of Pacira’s common stock, nor is it a substitute for the tender offer materials that Viatris will file with the SEC
on Schedule TO. At the time any such tender offer is commenced, Viatris will prepare and file a Tender Offer Statement, containing an offer to purchase, a form of letter of transmittal and other related tender offer documents, with the SEC, and
Pacira will file a Solicitation/Recommendation Statement on Schedule 14D-9 relating to such tender offer with the SEC. The offer to purchase shares will only be made pursuant to the offer to purchase, the letter of transmittal and other related
tender offer documents filed as a part of the Schedule TO. Pacira’s stockholders are strongly advised to read these tender offer materials carefully and in their entirety when they become available, as they may be
amended or supplemented from time to time, because they will contain important information about such tender offer that Pacira’s stockholders should consider prior to making any decisions with respect to such tender offer, including the terms and
conditions of the tender offer. The offer to purchase, letter of transmittal and other related tender offer documents, as well as the Solicitation/Recommendation Statement on Schedule 14D-9, will be sent to all stockholders of Pacira at no
expense to them. Once filed, stockholders of Pacira will be able to obtain a free copy of these documents and each of Viatris’ and Pacira’s other documents filed with the SEC at the website maintained by the
SEC at www.sec.gov. In addition, a copy of the offer to purchase, form of letter of transmittal and other related tender offer documents (once they become available) may be obtained free of charge by directing a request to Viatris at
InvestorRelations@viatris.com. A copy of the Solicitation/Recommendation Statement on Schedule 14D-9 (once it becomes available) also may be obtained free of charge by directing a request to Pacira at secretary@Pacira.com.
9
Contacts
|
Viatris
|
Pacira BioSciences
|
|||
|
Media:
|
Media:
|
|||
|
+
|
1.724.514.1968
|
Kim Hamilton
|
||
|
Communications@viatris.com
|
+1.908.721.7067
|
|||
|
Kim.Hamilton@pacira.com
|
||||
|
Jennifer Mauer
|
||||
|
Jennifer.Mauer@viatris.com
|
Sara Marino
|
|||
|
+1.973.370.5430
|
||||
|
Matt Klein
|
Sara.Marino@pacira.com
|
|||
|
Matthew.Klein@viatris.com
|
||||
|
Investors:
|
||||
|
Investors:
|
Susan Mesco
|
|||
|
+
|
1.724.514.1813
|
+1.973.451.4030
|
||
|
InvestorRelations@viatris.com
|
Susan.Mesco@pacira.com
|
|||
|
Bill Szablewski
|
||||
|
William.Szablewski@viatris.com
|
||||
10